{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:40:48Z","timestamp":1785894048801,"version":"3.56.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,5]],"date-time":"2021-09-05T00:00:00Z","timestamp":1630800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017209","name":"Fundaci\u00f3n Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017210","name":"Instituto de Investigacion Sanitaria de Santigao de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["RTI2018-099597-B-100"],"award-info":[{"award-number":["RTI2018-099597-B-100"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejpb.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T21:16:50Z","timestamp":1630963010000},"page":"195-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design, development, and characterization of an idebenone-loaded poly-\u03b5-caprolactone intravitreal implant as a new therapeutic approach for LHON treatment"],"prefix":"10.1016","volume":"168","author":[{"given":"Rub\u00e9n","family":"Varela-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Lema-Gesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gonz\u00e1lez-Barcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Otero-Espinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2021.09.001_b0005","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/S2214-109X(17)30293-0","article-title":"Vision Loss Expert Group, Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis","volume":"5","author":"Bourne","year":"2017","journal-title":"Lancet Glob. Health."},{"key":"10.1016\/j.ejpb.2021.09.001_b0010","first-page":"233","article-title":"Clinical approach to optic neuropathies","volume":"1","author":"Behbehani","year":"2007","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"10.1016\/j.ejpb.2021.09.001_b0015","first-page":"1144","article-title":"Hereditary optic neuropathies","volume":"18","author":"Newman","year":"2004","journal-title":"Eye Lond. Engl."},{"key":"10.1016\/j.ejpb.2021.09.001_b0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40265-016-0574-3","article-title":"Idebenone: A Review in Leber\u2019s Hereditary Optic Neuropathy","volume":"76","author":"Lyseng-Williamson","year":"2016","journal-title":"Drugs."},{"key":"10.1016\/j.ejpb.2021.09.001_b0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00002512-199405020-00007","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders","volume":"5","author":"Gillis","year":"1994","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejpb.2021.09.001_b0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-008-0596-1","article-title":"Pharmacokinetics and metabolism of idebenone in healthy male subjects","volume":"65","author":"Bodmer","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2021.09.001_b0035","unstructured":"European Medical Agency, Raxone\u00ae Technical Sheet, (2020). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/raxone-epar-product-information_en.pdf."},{"key":"10.1016\/j.ejpb.2021.09.001_b0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.2015.0047","article-title":"Recent Advances in Topical Ocular Drug Delivery","volume":"32","author":"Yellepeddi","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.09.001_b0045","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.09.001_b0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","article-title":"Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review","volume":"5","author":"Reardon","year":"2011","journal-title":"Patient Prefer. Adherence."},{"key":"10.1016\/j.ejpb.2021.09.001_b0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","article-title":"Patient-reported behavior and problems in using glaucoma medications","volume":"113","author":"Sleath","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2021.09.001_b0060","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2021.09.001_b0065","first-page":"245","article-title":"An in vitro analysis of a sustained release system for the treatment of denture stomatitis","volume":"12","author":"Schneid","year":"1992","journal-title":"Spec. Care Dent. Off. Publ. Am. Assoc. Hosp. Dent. Acad. Dent. Handicap. Am. Soc. Geriatr. Dent."},{"key":"10.1016\/j.ejpb.2021.09.001_b0070","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1023\/A:1015860030772","article-title":"In vitro evaluation of sustained drug release from biodegradable elastomer","volume":"8","author":"Wada","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2021.09.001_b0075","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1208\/pt060242","article-title":"Development of a dialysis in vitro release method for biodegradable microspheres","volume":"6","author":"D\u2019Souza","year":"2005","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2021.09.001_b0080","first-page":"464","article-title":"In vitro controlled drug release from loaded microspheres\u2013dose regulation through formulation","volume":"10","author":"Waters","year":"2007","journal-title":"J. Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci. Soc. Can. Sci. Pharm."},{"key":"10.1016\/j.ejpb.2021.09.001_b0085","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mnfr.200900090","article-title":"Repeated oral administration modulates the pharmacokinetic behavior of the chemopreventive agent phenethyl isothiocyanate in rats","volume":"54","author":"Konsue","year":"2010","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejpb.2021.09.001_b0090","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.2.6.1039","article-title":"Current advances in sustained-release systems for parenteral drug delivery","volume":"2","author":"Shi","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.09.001_b0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1211\/002235703765344577","article-title":"Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease","volume":"55","author":"Rainsford","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2021.09.001_b0100","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0142-9612(01)00291-5","article-title":"Dexamethasone\/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices","volume":"23","author":"Hickey","year":"2002","journal-title":"Biomaterials."},{"key":"10.1016\/j.ejpb.2021.09.001_b0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-3659(97)00267-8","article-title":"Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food","volume":"52","author":"Abrahamsson","year":"1998","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.08.030","article-title":"Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies","volume":"330","author":"Gao","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.09.001_b0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/193229680700100103","article-title":"Controlling acute inflammation with fast releasing dexamethasone-PLGA microsphere\/pva hydrogel composites for implantable devices","volume":"1","author":"Bhardwaj","year":"2007","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.ejpb.2021.09.001_b0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/j.1875-9114.1994.tb02833.x","article-title":"Use of in vitro and in vivo data in the design, development, and quality control of sustained-release decongestant dosage forms","volume":"14","author":"Mh","year":"1994","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejpb.2021.09.001_b0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0168-3659(02)00273-0","article-title":"Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur","volume":"85","author":"Zhang","year":"2002","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0130","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/jor.20193","article-title":"Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: an in vitro and in vivo study","volume":"24","author":"K\u00e4licke","year":"2006","journal-title":"J. Orthop. Res. Off. Publ. Orthop. Res. Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejpb.2005.02.005","article-title":"Two-month ciprofloxacin implants for multibacterial bone infections","volume":"60","author":"Castro","year":"2005","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV."},{"key":"10.1016\/j.ejpb.2021.09.001_b0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0168-3659(01)00502-8","article-title":"Reducing capsular thickness and enhancing angiogenesis around implant drug release systems","volume":"78","author":"Ratner","year":"2002","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0145","first-page":"143","article-title":"Biodegradable polymers for ocular drug delivery","volume":"215","author":"Kimura","year":"2001","journal-title":"Ophthalmol. J. Int. Ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd."},{"key":"10.1016\/j.ejpb.2021.09.001_b0150","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.progpolymsci.2010.04.002","article-title":"The return of a forgotten polymer\u2014Polycaprolactone in the 21st century","volume":"35","author":"Woodruff","year":"2010","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejpb.2021.09.001_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187221111794109529","article-title":"Recent advances in intraocular drug delivery systems","volume":"5","author":"Yasukawa","year":"2011","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2021.09.001_b0160","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1167\/iovs.16-19585","article-title":"Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma","volume":"57","author":"Kim","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2021.09.001_b0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1590\/S0100-40422011000600004","article-title":"Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies","volume":"34","author":"de Mello","year":"2011","journal-title":"Qu\u00edm. Nova"},{"key":"10.1016\/j.ejpb.2021.09.001_b0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.colsurfb.2012.01.021","article-title":"Polymeric particles for the controlled release of human amylin","volume":"94","author":"Guerreiro","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2021.09.001_b0175","doi-asserted-by":"crossref","unstructured":"J. Siepmann, R.A. Siegel, M.J. Rathbone (Eds.), Fundamentals and Applications of Controlled Release Drug Delivery, Springer US, 2012. https:\/\/doi.org\/10.1007\/978-1-4614-0881-9.","DOI":"10.1007\/978-1-4614-0881-9"},{"key":"10.1016\/j.ejpb.2021.09.001_b0180","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1002\/adma.201202080","article-title":"Materials for drug delivery: innovative solutions to address complex biological hurdles","volume":"24","author":"Mitragotri","year":"2012","journal-title":"Adv. Mater. Deerfield Beach Fla."},{"key":"10.1016\/j.ejpb.2021.09.001_b0185","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1021\/acsami.0c18926","article-title":"Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan\/TPP and Chitosan\/Sulfobutylether-\u03b2-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment","volume":"13","author":"Varela-Fern\u00e1ndez","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2021.09.001_b0190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/156720109787048302","article-title":"Poly (D, L-lactide) nanosuspensions of risperidone for parenteral delivery: formulation and in-vitro evaluation","volume":"6","author":"Muthu","year":"2009","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.09.001_b0195","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/js950474+","article-title":"Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers","volume":"85","author":"Calvo","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.09.001_b0200","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s11095-010-0275-7","article-title":"Anticancer drug-loaded nanospheres based on biodegradable amphiphilic \u03b5-caprolactone and carbonate copolymers","volume":"27","author":"Yan","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2021.09.001_b0205","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1208\/s12249-011-9625-y","article-title":"Injectability Evaluation: An Open Issue","volume":"12","author":"Cilurzo","year":"2011","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2021.09.001_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2021.09.001_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114835","article-title":"Controlled Release of Dutasteride from Biodegradable Microspheres, Vitro and In Vivo Studies","volume":"9","author":"Xie","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejpb.2021.09.001_b0220","first-page":"287","article-title":"Hen\u2019s egg chorioallantoic membrane test for irritation potential, Food Chem","volume":"23","author":"Luepke","year":"1985","journal-title":"Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0887-2333(90)90147-L","article-title":"A national validation project of alternative methods to the Draize rabbit eye test","volume":"4","author":"Kalweit","year":"1990","journal-title":"Toxicol. Vitro Int. J. Publ. Assoc. BIBRA."},{"key":"10.1016\/j.ejpb.2021.09.001_b0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0887-2333(93)90055-A","article-title":"Validation study of alternatives to the Draize eye irritation test in Germany: Cytotoxicity testing and HET-CAM test with 136 industrial chemicals","volume":"7","author":"Spielmann","year":"1993","journal-title":"Toxicol. Vitro Int. J. Publ. Assoc. BIBRA"},{"key":"10.1016\/j.ejpb.2021.09.001_b0235","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jconrel.2005.10.005","article-title":"Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems","volume":"110","author":"Luan","year":"2006","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0240","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/jps.21158","article-title":"PLGA Nanoparticles for Oral Delivery of Hydrophobic Drugs: Influence of Organic Solvent on Nanoparticle Formation and Release Behavior In Vitro and In Vivo Using Estradiol as a Model Drug","volume":"97","author":"Sahana","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.09.001_b0245","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2005.02.025","article-title":"Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres","volume":"106","author":"Ibrahim","year":"2005","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.01.016","article-title":"Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo","volume":"119","author":"Mittal","year":"2007","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0255","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijpharm.2009.07.017","article-title":"Protein-loaded PLGA microparticles engineered by flow focusing: physicochemical characterization and protein detection by reversed-phase HPLC","volume":"380","author":"Holgado","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.09.001_b0260","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF02648045","article-title":"Finite element modeling of drug distribution in the vitreous humor of the rabbit eye","volume":"25","author":"Friedrich","year":"1997","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2021.09.001_b0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-409X(01)00187-9","article-title":"Pharmacokinetic model for in vivo\/in vitro correlation of intravitreal drug delivery","volume":"52","author":"Tojo","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.09.001_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045182","article-title":"Idebenone protects against retinal damage and loss of vision in a mouse model of Leber\u2019s hereditary optic neuropathy","volume":"7","author":"Heitz","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ejpb.2021.09.001_b0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0939-6411(99)00034-X","article-title":"Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants","volume":"48","author":"Rothen-Weinhold","year":"1999","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV"},{"key":"10.1016\/j.ejpb.2021.09.001_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.01.044","article-title":"Poly-epsilon-caprolactone microspheres and nanospheres: an overview","volume":"278","author":"Sinha","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.09.001_b0285","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0079-6700(97)00048-8","article-title":"Biodegradable polymers for the controlled release of ocular drugs","volume":"23","author":"Merkli","year":"1998","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejpb.2021.09.001_b0290","first-page":"95","article-title":"5-Fluorouracil-loaded poly(\u03b5-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer","volume":"7","author":"Ortiz","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2021.09.001_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020160","article-title":"Long-Acting Paliperidone Parenteral Formulations Based on Polycaprolactone Nanoparticles; the Influence of Stabilizer and Chitosan on In Vitro Release, Protein Adsorption, and Cytotoxicity","volume":"12","author":"Elmowafy","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2021.09.001_b0300","doi-asserted-by":"crossref","unstructured":"H. Sheardown, W.M. Saltzman, Novel Drug Delivery Systems for Posterior Segment Ocular Disease, in: J. Tombrain-Tink, C.J. Barnstable (Eds.), Ocul. Angiogenesis Dis. Mech. Ther., Humana Press, Totowa, NJ, 2006: pp. 393\u2013408. https:\/\/doi.org\/10.1007\/978-1-59745-047-8_22.","DOI":"10.1007\/978-1-59745-047-8_22"},{"key":"10.1016\/j.ejpb.2021.09.001_b0305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","article-title":"Drug delivery systems for vitreoretinal diseases","volume":"23","author":"Yasukawa","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2021.09.001_b0310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-3659(00)00267-4","article-title":"Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis","volume":"68","author":"Kunou","year":"2000","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2021.09.001_b0315","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/02713680600719036","article-title":"Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes","volume":"31","author":"Fialho","year":"2006","journal-title":"Curr. Eye Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:45:26Z","timestamp":1760546726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":63,"alternative-id":["S0939641121002332"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.09.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, development, and characterization of an idebenone-loaded poly-\u03b5-caprolactone intravitreal implant as a new therapeutic approach for LHON treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}